Page 19 - College Advantage - A Publication of the American College of Allergy, Asthma & Immunology – Winter 2024
P. 19
Winter 2024 19
FDA-APPROVED FOR
5 INDICATIONS
CONSIDER DUPIXENT
FOR YOUR APPROPRIATE PATIENTS
Learn more at Dupixenthcp.com
© 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. DUP.23.03.0192 04/2023 DUPIXENT® is a registered trademark of Sanofi Biotechnology.
Return to page 1
